Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
Enfusion , Inc. (NYSE:ENFN) Chief Financial Officer Bradley Herring recently sold a portion of his holdings in the company. According to a Form 4 filed with the Securities and Exchange Commission, Herring sold 1,533 shares of Class A common stock on March 3, 2025. The shares were sold at a weighted average price of $11.481, generating a total value of approximately $17,600. The transaction comes as the $1.47 billion market cap company trades near its 52-week high of $11.80, having gained over 41% in the past six months. InvestingPro analysis indicates the stock is currently trading close to its Fair Value.
The transaction was executed to cover tax withholding obligations related to the issuance of shares, rather than as a discretionary trade. Following this sale, Herring retains ownership of 329,334 shares in Enfusion. The company maintains strong financial health with a current ratio of 3.42 and revenue growth of 15.5% over the last twelve months. For deeper insights into Enfusion’s financial metrics and additional analysis, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Enfusion Inc. has announced its fourth-quarter earnings for 2024, which coincided with the company’s agreement to be acquired by Clearwater Analytics for $11.25 per share. This acquisition price is a 13% premium over Enfusion’s last closing price before the announcement and values the company at approximately 6.4 times its projected FY25 enterprise value/revenue. Following this development, Stifel analysts downgraded Enfusion’s stock from Buy to Hold and adjusted the price target to align with the acquisition price of $11.25. Morgan Stanley (NYSE:MS) also downgraded Enfusion from Overweight to Equal-weight, citing the acquisition as a catalyst for the change, although they increased the price target to match the offer price.
The acquisition is seen as a strategic move to expedite value realization for shareholders, addressing concerns such as Enfusion’s limited public float and its dependency on the startup hedge fund sector. Stifel analysts consider the acquisition price fair and believe the likelihood of a higher competing bid is slim. Both Stifel and Morgan Stanley’s revised price targets reflect the agreed acquisition price, indicating expectations for the stock to stabilize at this level. The acquisition process continues to be a focal point for investors as it represents a significant transition for Enfusion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.